Author

Kristen Daniels

Observed name: Daniels, Kristen

Institution: Boehringer Ingelheim (United States)

Observed institutions: Boehringer Ingelheim (Germany), Boehringer Ingelheim (United States)

OpenAlex ID: A5063649965

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

2018 · David Brown, Kazuyuki Nakagome, et al. · Schizophrenia Bulletin · 41

Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-Month, Randomized, Double-Blind, Placebo-Controlled Study

2013 · James Thrasher, Kristen Daniels, et al. · Endocrine Practice · 20

A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale

2020 · Richard S. E. Keefe, Scott W. Woods, et al. · Early Intervention in Psychiatry · 14

Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin

2012 · James Thrasher, Kristen Daniels, et al. · Expert Opinion on Pharmacotherapy · 10

AI-Based Adherence Prediction for Patients: Leveraging a Mobile Application to Improve Clinical Trials

2023 · Dooti Roy, Zheng Zhu, et al. · CNS Spectrums · 6

A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia

2017 · David Brown, Kristen Daniels, et al. · Neurology and Therapy · 6

S190. Prevention of Relapse in Schizophrenia: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306

2018 · Michael Sand, David Brown, et al. · Biological Psychiatry · 2

T205. Effect of BI 409306 on Positive and Negative Syndrome Scale in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

2018 · Michael Sand, Kazuyuki Nakagome, et al. · Biological Psychiatry · 1

21. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study

2017 · Michael Sand, David Brown, et al. · Schizophrenia Bulletin · 1

Effect of BI 409306 on Positive and Negative Syndrome Scale in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

2018 · Sand, Michael, Nakagome, Kazuyuki, et al. · RWTH Publications (RWTH Aachen)

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study

2017 · Sand, Michael, Brown, David, et al. · RWTH Publications (RWTH Aachen)

Works count: 13

Citation count: 101

H-index: 6

I10-index: 4